Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

BackgroundInhibition of mitogen-activated protein kinase (MEK, also known as MAPK2, MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has shown promising effects on B-raf-mutated and some RAS (rat sarcoma)-activated tumors in clinical trials. The objective of this study is to examine the efficacy of a novel allosteric MEK inhibitor RO4987655 in K-ras-mutated human tumor xenograft models using [18F] FDG-PET imaging and proteomics technology.Methods[18F] FDG uptake was studied in human lung carcinoma xenografts from day 0 to day 9 of RO4987655 therapy using microPET Focus 120 (CTI Concorde Microsystems, Knoxville, TN, USA). The expression levels of GLUT1 and hexokinase 1 were examined using semi-quantitative fluorescent immunohistochemistry (fIHC). The in vivo effects of RO4987655 on MAPK/PI3K pathway components were assessed by reverse phase protein arrays (RPPA).ResultsWe have observed modest metabolic decreases in tumor [18F] FDG uptake after MEK inhibition by RO4987655 as early as 2 h post-treatment. The greatest [18F] FDG decreases were found on day 1, followed by a rebound in [18F] FDG uptake on day 3 in parallel with decreasing tumor volumes. Molecular analysis of the tumors by fIHC did not reveal statistically significant correlations of GLUT1 and hexokinase 1 expressions with the [18F] FDG changes. RPPA signaling response profiling revealed not only down-regulation of pERK1/2, pMKK4, and pmTOR on day 1 after RO4987655 treatment but also significant up-regulation of pMEK1/2, pMEK2, pC-RAF, and pAKT on day 3. The up-regulation of these markers is interpreted to be indicative of a reactivation of the MAPK and activation of the compensatory PI3K pathway, which can also explain the rebound in [18F] FDG uptake following MEK inhibition with RO4987655 in the K-ras-mutated human tumor xenografts.ConclusionsWe have performed the first preclinical evaluation of a new MEK inhibitor, RO4987655, using a combination of [18F] FDG-PET imaging and molecular proteomics. These results provide support for using preclinical [18F] FDG-PET imaging in early, non-invasive monitoring of the effects of MEK and perhaps other Ras/MAPK signaling pathway inhibitors, which should facilitate a wider implementation of clinical [18F] FDG-PET to optimize their clinical use.

[1]  J. Schellens,et al.  Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[2]  M. Pawlak,et al.  Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA)* , 2015, Molecular & Cellular Proteomics.

[3]  Khin Thway,et al.  Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.

[4]  H. Tonami,et al.  Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer , 2000, European Journal of Nuclear Medicine.

[5]  H. Tonami,et al.  Correlation of Glut-1 glucose transporter expression with. , 2000, European journal of nuclear medicine.

[6]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[7]  Frances S. Ligler,et al.  Evanescent wave fluorescence biosensors: Advances of the last decade. , 2016, Biosensors & bioelectronics.

[8]  Chunrong Yu,et al.  BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. , 2008, Cancer research.

[9]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[10]  Rodney J Hicks,et al.  In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.

[11]  Kazuo Miyasaka,et al.  Lung Tumors Evaluated With FDG-PET and Dynamic CT: The Relationship Between Vascular Density and Glucose Metabolism , 2002, Journal of computer assisted tomography.

[12]  P. Chow,et al.  2-[18f]-2-deoxy-d-glucose (fdg) uptake in human tumor cells is related to the expression of glut-1 and hexokinase ii , 2008, Acta radiologica.

[13]  Sylvain Meloche,et al.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy , 2010, Journal of hematology & oncology.

[14]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[15]  C. Arteaga,et al.  Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers , 2009, Clinical Cancer Research.

[16]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[17]  N. Rosen,et al.  Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. , 2013, Cancer research.

[18]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[19]  N. van Bruggen,et al.  FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973 , 2012, EJNMMI Research.

[20]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[21]  F. Rojo,et al.  First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors , 2012, Clinical Cancer Research.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[23]  S. Loi,et al.  Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. , 2013, Cancer treatment reviews.

[24]  C. Lukacs,et al.  Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. , 2011, Bioorganic & medicinal chemistry letters.

[25]  H. Tonami,et al.  FDG PET measurement of the proliferative potential of non-small cell lung cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Emanuel F Petricoin,et al.  Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. , 2007, Cancer genomics & proteomics.

[27]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[30]  Emanuel F Petricoin,et al.  Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[31]  S. Stone-Elander,et al.  [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models , 2013, EJNMMI Research.

[32]  F. Gleeson,et al.  Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials , 2012, The Journal of Nuclear Medicine.

[33]  Prahlad T. Ram,et al.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.

[34]  N. Avril.  GLUT1 expression in tissue and (18)F-FDG uptake. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[36]  T. Manabe,et al.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.

[37]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[39]  L. Mortelmans,et al.  Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[42]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[43]  Carlotta Costa,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[44]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Adjei,et al.  Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy , 2008, Clinical Cancer Research.

[46]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[47]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[48]  David B Solit,et al.  Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response , 2010, Clinical Cancer Research.

[49]  W. Oyen,et al.  Biological correlates of FDG uptake in non-small cell lung cancer. , 2007, Lung cancer.

[50]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[51]  W. Weiss,et al.  It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  J. Bankson,et al.  Monitoring Therapy with MEK Inhibitor U0126 in a Novel Wilms Tumor Model in Wt1 Knockout Igf2 Transgenic Mice Using 18F-FDG PET with Dual-Contrast Enhanced CT and MRI: Early Metabolic Response Without Inhibition of Tumor Growth , 2012, Molecular Imaging and Biology.

[53]  P. Sorger,et al.  Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays , 2013, Oncogene.

[54]  Wh Sit,et al.  Cancer Genomics & Proteomics , 2007 .

[55]  Kalle Jonasson,et al.  Tissue Profiling of the Mammalian Central Nervous System Using Human Antibody-based Proteomics* , 2009, Molecular & Cellular Proteomics.

[56]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.